evidence: ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; p = 0.0037)
intervention: ProtecT trial patients
comparator: Patients excluded from the ProtecT
outcome: Mortality rates